C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays lowered the firm’s price target on C4 Therapeutics to $5 from $10, while maintaining an Overweight rating on the shares. The firm updated its biotechnology price targets as part of its 2026 sector outlook. On December 2, TD Cowen initiated coverage of C4 Therapeutics with a Buy rating but set no price target on the company’s shares. The firm highlighted that the company distin ...

Core Insights - C4 Therapeutics, Inc. is participating in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, indicating its active engagement in the healthcare investment community [1][2] - The company focuses on advancing targeted protein degradation science to develop innovative medicines aimed at transforming patient outcomes [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker CCCC [3] - The company is dedicated to creating a new generation of medicines through targeted protein degradation, which aims to address difficult-to-treat diseases [3] - C4T utilizes its TORPEDO platform to design and optimize small-molecule medicines, enhancing the potential to overcome drug resistance and improve patient outcomes [3] Event Details - The fireside chat will take place on December 3, 2025, at 3:25 pm ET, with a live webcast available on the company's website [2] - An archived replay of the webcast will be accessible for approximately 90 days following the live event [2]